Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 DDW Annual Meeting
The presentations will take place during the DDW Annual Meeting being held virtually from
Oral Presentations:
Title (Presenter): |
Interim Results of an Open-Label Extension Study of Antolimab, an Anti-Siglec-8 Antibody, for the Treatment of Patients with Eosinophilic Gastritis and/or Eosinophilic Enteritis ( |
Session (Time): | Esophageal Diseases, Eosinophilic Esophagitis: Clinical ( |
Title (Presenter): |
Histologic and Symptomatic Improvement Across Multiple Forms of Eosinophilic Gastrointestinal Diseases in ENIGMA, A Randomized, Double-Blind, Placebo-Controlled Trial of Antolimab (AK002) ( |
Session (Time): | Esophageal Diseases, Eosinophilic Esophagitis: Clinical – Distinguished Abstract Plenary ( |
Title (Presenter): | Primary Results of A Phase 1 Multicenter Open-Label Study of Antolimab, an Anti-Siglec-8 Antibody, for the Treatment of Patients with Chronic Gastrointestinal Symptoms and Elevated Gastric and/or Duodenal Mast Cells ( |
Session (Time): | Functional GI and Motility Disorders, Functional Dyspepsia, Nausea and Vomiting ( |
Title (Presenter): | EGID Biopsies Have Functionally Distinct and Activated Mast Cells that Contribute to Disease Pathogenesis and are Inhibited by an Anti-Siglec-8 Antibody, Antolimab (AK002) ( |
Session (Time): | Esophageal Diseases, Eosinophilic Esophagitis: Translational or Basic ( |
Poster Presentations:
Title (Presenter): |
Mast Cells are Significantly Activated in Patients with Ulcerative Colitis and are Inhibited by an Anti-Siglec-8 Antibody, Antolimab (AK002) ( |
Session (Time): | Basic Science, IBD: Cytokines, Signaling and Receptors ( |
Title (Presenter): |
Mast Cell Level and Clinical Correlates in Patients with Eosinophilic Gastritis and Gastroenteritis ( |
Session (Time): | Esophageal Diseases, Eosinophilic Esophagitis: Translational or Basic ( |
Title (Presenter): |
Establishment of |
Session (Time): | Esophageal Diseases, Eosinophilic Esophagitis: Translational or Basic ( |
Following the presentations, the posters and slides will be available on the
About
Source:
Investor Contact:Adam Tomasi , President & COO investors@allakos.com Media Contact:Denise Powell denise@redhousecomms.com
Source: Allakos Inc.